10q10k10q10k.net
Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc.OTLKEarnings & Financial Report

Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)

Outlook Therapeutics, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing ophthalmic biologic therapies for patients with unmet medical needs. Its core pipeline targets common sight-threatening eye conditions, with operations spanning North America, Europe, and key Asia-Pacific regional markets.

Q1 2026Q4 2025Q2 2025Q1 2025Q1 2023

OTLK Q1 FY2026 Key Financial Metrics

Revenue

$0

Gross Profit

$-1.2M

Operating Profit

$-13.5M

Net Profit

$-23.1M

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

YoY Growth

N/A

EPS

$-0.38

Outlook Therapeutics, Inc. Q1 FY2026 Financial Summary

Outlook Therapeutics, Inc. reported revenue of $0 for Q1 FY2026, with a net profit of $-23.1M (down 232.7% YoY) (N/A margin). Cost of goods sold was $1.2M, operating expenses totaled $12.2M.

Key Financial Metrics

Total Revenue$0
Net Profit$-23.1M
Gross MarginN/A
Operating MarginN/A
Report PeriodQ1 FY2026

Outlook Therapeutics, Inc. Quarterly Revenue & Net Profit History

Outlook Therapeutics, Inc. results over the last 5 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q1 FY2026$0—$-23.1MN/A
Q4 FY2025$-264.2K+60.3%$-13.3M5032.2%
Q2 FY2025$-18.5K+99.4%$-46.4M250552.4%
Q1 FY2025$48.9K-74.1%$17.4M35550.9%
Q1 FY2023$-2.4M-596.5%$-18.7M762.2%

Income Statement

Q1 2023Q1 2025Q2 2025Q4 2025Q1 2026
Revenue$-2.4M$48881$-18502$-264156$0
YoY Growth-596.5%-74.1%99.4%60.3%N/A

Balance Sheet

Q1 2023Q1 2025Q2 2025Q4 2025Q1 2026
Assets$62.7M$17.0M$19.1M$18.6M$18.2M
Liabilities$46.9M$67.3M$51.5M$50.8M$56.8M
Equity$15.8M$-50.3M$-32.5M$-32.2M$-38.5M

Cash Flow

Q1 2023Q1 2025Q2 2025Q4 2025Q1 2026
Operating CF$-8.9M$-11.0M$-16.6M$-12.4M$-14.9M